Trump Secures Drug Pricing Deals With Nine Pharma Companies 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
France Targets Shein, Temu With Fast-Fashion Fees 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Rejects Apple Trade Secret Theft Claims 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
CIA-Linked Investor Helped Quantum Systems Expand in US 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Add as a preferred source on Google
VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Wednesday, March 14, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss fourth quarter 2017 year-end financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 8777644.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
